Mr. Blickenstaff served as the President and Chief Executive Officer of Biosite Incorporated (NASDAQ: BSTE), a public medical diagnostics company, from April 1988 until its acquisition in 2007. He is also a director of several privately-held medical products companies. Prior to joining Biosite, he held various positions in finance, operations, research management, sales management, strategic planning, and marketing with Baxter Travenol, National Health Laboratories and Hybritech Incorporated. Mr. Blickenstaff received a B.A. from Loyola Marymount College and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.
Mr. Adams has been the President and Chief Executive Officer of Protein Sciences Corporation, a biopharmaceutical service company since 1995. He has founded a number of life sciences companies, among them Biogen, where he served as the first Chief Executive Officer. Mr. Adams holds a B.A. degree in Chemistry from Cornell University and a J.D. magna cum laude from New York University School of Law.
Dr. Bailey has been Managing Director of Investment Banking of MDB Capital Group LLC, an investment banking firm, since 2004. Prior to joining MDB Capital, he was a Life Sciences Analyst at Participating Capital, an investment banking firm, since 1995. Dr. Bailey holds a M.D. degree from the University of Western Ontario.
Dr. Hung became our President and Chief Executive Officer, and a member of our Board of Directors, when we acquired our subsidiary Medivation Neurology, Inc. in December, 2004. He also served as President, Chief Executive Officer, and Director of Medivation Neurology, Inc. since its inception in September, 2003. From 1998 until 2001, Dr. Hung served as Chief Scientific Officer (1998-1999) and as President, Chief Executive Officer and Director (1999-2001) of ProDuct Health, Inc., a privately-held medical device company. ProDuct Health, Inc. took its first product (a breast cancer cytological diagnostic product) from a prototype design, through a 507 patient clinical trial and through FDA marketing clearance in 16 months, and was acquired in 2001 by Cytyc Corporation for $167 million, after having spent only approximately $22 million in total development costs. From 1994-1998, Dr. Hung served in various senior positions at Chiron Corporation, a public biotechnology company, with his last position being Vice President of Lead Discovery and Development and Vice President of New Projects. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in Biology from Harvard College.
Former Company Group Chairman DePuy Orthopedics, Inc. Former President Centocor, Inc.
Mr. Vernon has 23 years experience serving in senior executive positions at various Johnson & Johnson companies, including Company Group Chairman of DePuy Orthopedics, Inc. (2004-2005), President of Centocor, Inc. (2001-2004), President of McNeil Consumer Healthcare (1999-2001), and President Worldwide of the Johnson & Johnson Merck Joint Venture. Mr. Vernon received a B.A. from Lawrence University and an M.B.A. from the Northwestern University Kellogg Graduate School of Management.
Stock transaction information provided by EDGAR Online. Medivation, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
Contact the Board
You can contact Medivation, Inc.'s Board of Directors to provide comments, to report concerns, or to ask a question, at the following address.
Corporate Secretary
Medivation, Inc. 201 Spear St. 3rd Floor San Francisco, CA 94105 United States
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.
Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Medivation, Inc. board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as:
Product complaints
Product inquiries
New product suggestions
Resumes and other forms of job inquiries
Surveys
Business solicitations or advertisements
In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.
= Chairman of the Board
= Chair 
= Member
= Independent Director
